FDA authorizes IND for Gain Therapeutics' GT-02287, permitting Phase 2 Parkinson's study

Gain Therapeutics, Inc.

FDA authorized IND for GT-02287, enabling Phase 2 clinical development in Parkinson's disease with or without GBA1 mutation.
Phase 2a study of oral GT-02287 in early Parkinson's patients planned; sites in U.S., Australia, and Europe.
Phase 2a initiation expected in Q3 2026; Phase 1a/b were conducted in Australia.
FDA clearance is a key regulatory milestone for Gain Therapeutics' lead candidate.

Featured in Daily 8-K Digest

Selected #7 for 2026-06-29. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.